Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in Fibrotic Hypersensitivity Pneumonitis
NCT02958917Phase 2Terminated
- Start
- Jun 2017
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in fibrotic hypersensitivity pneumonitis (CHP) comparing Pirfenidone with Placebo (2 arms). Primary endpoint: Percent Predicted Forced Vital Capacity at 52 weeks. Started Jun 2017; status: terminated.
02
Drugs
pirfenidone
03
Conditions
fibrotic hypersensitivity pneumonitis (CHP)
Beyond the preview
Go deeper on NCT02958917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02958917.